The European middle-market's preference for sole-lender deals contrasts with the syndicated US market. This allows lenders to design their own tight credit agreements, preventing value leakage and prioritizing downside protection—the most critical factor for a capped-return loan product.

Despite being Europe's largest economy, Germany is only the fourth-largest issuer of direct lending. Its vast "Mittelstand" (middle-market) has historically relied on banks. PGIM sees this as a major structural opportunity as cultural norms shift and these well-run companies begin to access private credit solutions.

The US corporate market is 75% financed by capital markets, while Europe's is ~80% bank-financed. This structural inversion means Europe is undergoing a long-term, multi-decade shift toward institutional lending, creating a sustained tailwind for private credit growth that is far from mature.

While the US private credit market is saturated, Europe's middle-market offers higher spreads (north of 600 basis points) and lower leverage. This opportunity is most pronounced in non-sponsor deals, a segment where large banks and public markets are less active, creating a lucrative niche.

Unlike its reputation, the healthcare sector faces substantial challenges from regulation, pricing pressure, and difficulties in passing on costs. This makes it a deceptively risky area for credit investors who must perform careful selection rather than treating it as a defensive play.

The current unpredictability at the FDA is so pronounced that prominent biotech investor Peter Kolchinsky of RA Capital is now advising his portfolio companies to de-risk development by conducting early-stage clinical trials outside the United States. This marks a significant strategic shift for US-based innovators.

Beyond funding and regulatory hurdles, Europe's restrictive drug pricing environment is a fundamental threat. It discourages pharmaceutical companies, including Europe's own, from investing in the region as they prioritize the more profitable US market. This ultimately undermines the entire local R&D ecosystem.

PGIM's middle-market portfolio focuses exclusively on first-lien, senior-secured, cash-pay-only loans. This conservative, "boring in a good way" approach avoids structural and collateral risk from second-liens or PIK toggles, ensuring stable cash income and insulating investors from exogenous outcomes.

Large European banks are not absent from lending, but they prefer the simplicity and regulatory ease of large, portfolio-level financing over complex, single-company underwriting. This strategic focus leaves a significant funding gap in the €100-€400M facility size range for private credit funds to fill.